ID   Mel1617
AC   CVCL_DG51
SY   MEL1617; Mel-1617
DR   cancercelllines; CVCL_DG51
DR   GEO; GSM1199180
DR   Progenetix; CVCL_DG51
DR   Wikidata; Q54905149
RX   PubMed=21156289;
RX   PubMed=23285177;
RX   PubMed=24055054;
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=21156289).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21156289).
CC   Omics: Array-based CGH.
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7928 ! WM164
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 11
//
RX   PubMed=21156289; DOI=10.1016/j.ccr.2010.11.023;
RA   Villanueva J., Vultur A., Lee J.T., Somasundaram R.,
RA   Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X.-W.,
RA   Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K.,
RA   Pushparajan A., Hayden J.E., Dahlman K.B., Laquerre S.G., McArthur G.A.,
RA   Sosman J.A., Nathanson K.L., Herlyn M.;
RT   "Acquired resistance to BRAF inhibitors mediated by a RAF kinase
RT   switch in melanoma can be overcome by cotargeting MEK and
RT   IGF-1R/PI3K.";
RL   Cancer Cell 18:683-695(2010).
//
RX   PubMed=23285177; DOI=10.1371/journal.pone.0052760;
RA   Schayowitz A.B., Bertenshaw G.P., Jeffries E., Schatz T., Cotton J.,
RA   Villanueva J., Herlyn M., Krepler C., Vultur A., Xu W., Yu G.H.,
RA   Schuchter L.M., Clark D.P.;
RT   "Functional profiling of live melanoma samples using a novel automated
RT   platform.";
RL   PLoS ONE 7:E52760-E52760(2012).
//
RX   PubMed=24055054; DOI=10.1016/j.celrep.2013.08.023;
RA   Villanueva J., Infante J.R., Krepler C., Reyes-Uribe P., Samanta M.,
RA   Chen H.-Y., Li B., Swoboda R.K., Wilson M., Vultur A.,
RA   Fukunaga-Kalabis M., Wubbenhorst B., Chen T.Y., Liu Q., Sproesser K.,
RA   DeMarini D.J., Gilmer T.M., Martin A.-M., Marmorstein R., Schultz D.C.,
RA   Speicher D.W., Karakousis G.C., Xu W., Amaravadi R.K., Xu X.-W.,
RA   Schuchter L.M., Herlyn M., Nathanson K.L.;
RT   "Concurrent MEK2 mutation and BRAF amplification confer resistance to
RT   BRAF and MEK inhibitors in melanoma.";
RL   Cell Rep. 4:1090-1099(2013).
//